BioAffinity Technologies

Addressing a critical need to find cancer early and treat cancer specifically, bioAffinity Technologies, Inc. develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath® Flow Cytometry for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.